Prevention of _Helicobacter pylori_ infection by lactobacilli in a gnotobiotic murine model

A M A Kabir, Y Aiba, A Takagi, S Kamiya, T Miwa, Y Koga

Abstract

**Background**—*Helicobacter pylori* is a bacterium which causes gastric inflammatory diseases. Oral inoculation of *H. pylori* usually results in only a temporary colonisation without a successful infection in the stomach of conventional mice in which lactobacilli are the predominant indigenous bacteria.

**Aim**—To determine whether lactobacilli exert an inhibitory effect on colonisation by *H. pylori* in the stomach.

**Methods**—The effects of *H. pylori* on attachment to murine and human gastric epithelial cells and the *H. pylori* mediated release of interleukin-8 (IL-8) by these cells were examined in vitro. *Lactobacillus salivarius* infected gnotobiotic BALB/c mice and control germ free mice were inoculated orally with *H. pylori* to examine whether *L. salivarius* can inhibit colonisation by *H. pylori*.

**Results**—*L. salivarius* inhibited both the attachment and IL-8 release in vitro. *H. pylori* could not colonise the stomach of *L. salivarius* infected gnotobiotic BALB/c mice, but colonised in large numbers and subsequently caused active gastritis in germ free mice. In addition, *L. salivarius* given after *H. pylori* implantation could eliminate colonisation by *H. pylori*.

**Conclusion**—These findings suggest the possibility of lactobacilli being used as probiotic agents against *H. pylori*.

_Gut_ 1997; 41: 49–55

Keywords: Helicobacter pylori; Lactobacillus salivarius; germ free mice; probiotics

_Helicobacter pylori_ is a microaerophilic and Gram negative bacillus that causes chronic gastritis and peptic ulcer diseases. This bacterium is also suspected to be involved in the genesis of gastric cancer.1 *H. pylori* infection usually occurs within a few years after birth and persists chronically thereafter. In developing countries, up to 80% of the population may become infected by age 20.2 Administration of an effective vaccine thus needs to be carried out in such countries in order to prevent young people from being infected by *H. pylori*. However, the efficacy of a vaccine against this bacterium is still uncertain, because a natural immunity seems to be inadequate for curing the infection in spite of an active immune response at the site of colonisation of _H. pylori_. Moreover, the vaccine may also cause autoimmune inflammation since some protein species of *H. pylori* bear a close homology to such eukaryotic proteins as heat shock proteins.3 4 Therefore, a new device free of such problems needs to be developed together with a conventional vaccine to achieve complete prevention of *H. pylori* infection.

Attachment to cells is a prerequisite for the colonisation of the epithelial surface by many bacteria and this phenomenon is mediated by the molecules on the bacterial surface, which subsequently recognise proteins or glycoconjugates on the surface of eukaryotic cells. An ultrastructural analysis of gastric mucosa infected with *H. pylori* in vitro showed this bacterium to adhere to the gastric epithelium strongly enough to cause an effacement of the epithelial microvilli and also form adherence pedestals.5 6 Such close contact of *H. pylori* with the epithelium results in the secretion of cytokines such as interleukin-8 (IL-8) and IL-1, which are considered to play an important role in the occurrence of gastric lesions.7 It is thus expected that an agent capable of inhibiting the attachment of *H. pylori* could also prevent the colonisation and subsequent symptomatic gastric disease caused by this bacterium in the stomach.

The gastrointestinal (GI) tract is colonised by a variety of indigenous bacteria. Lactobacilli are the predominant bacteria found in the normal fasting stomach although their number is small, ranging from only 0 to 10⁵ per ml of fluid.8 The inhibitory effect of lactobacilli on the growth of _H. pylori_ has been previously demonstrated in vitro.9 Karita et al10 11 reported that the oral inoculation of _H. pylori_ resulted in a continuous colonisation of the gastric mucosa in decontaminated mice; however the colonisation was only temporary in the non-decontaminated mice in which lactobacilli are the predominant indigenous inhabitants. It was thus suggested that lactobacilli exert an inhibitory effect on colonisation of the stomach by _H. pylori_. To evaluate this possibility, we have investigated whether lactobacilli inhibit the attachment of _H. pylori_ to epithelial cells in vitro and whether the lactobacillus exerting such an inhibitory effect can also prevent the colonisation and development of inflammatory lesions in the stomach using a gnotobiotic murine model.

**Methods**

**BACTERIAL STRAINS**

_H. pylori_ No 112 (cag A⁺, vacuolating toxin*), No 130 (cag A⁺, vacuolating toxin*), and No 135 (cag A⁺, vacuolating toxin*). were isolated by us from gastric biopsy materials of patients treated at Tokai University Hospital. _H. pylori_ NCTC 11637 was purchased from the American Type Culture Collection (ATCC), Rockville,
Maryland, USA. They were grown on Skirrow plates to count the number of colony forming units (CFU). Identification of clinical isolates such as *H. pylori* was done by Gram stain morphology and by using API CAMPY Kit (Biomerieux, Marcy-l’Étoile, France) after the colony was transferred to a brain/heart infusion agar plate (Difco Laboratories, Detroit, Michigan, USA). The cytototoxicity assay to detect the vacuolating toxin was performed by a previously described method. The colony of *H. pylori* was then transferred to Brucella broth (Difco Laboratories) containing 5% FCS and incubated at 37°C for 72 hours. The broth cultures were harvested by centrifugation at 3000 g for 15 minutes, resuspended in a medium containing 10% skimmed milk and 1% sodium glutamate, and frozen at −70°C until use. Using these procedures, the clinically isolated strains of *H. pylori* underwent in vitro passage four times and were then kept frozen as the stock for experimental use. For the adherence assay, *H. pylori* from the stock was cultured again in a brain/heart infusion agar (Difco) containing 5% horse blood in 5% O₂, 10% CO₂, and 85% N₂ at 37°C for four days and then used. For inoculation into mice, *H. pylori* from the stock was grown in Brucella broth containing 5% FCS in the gas described above at 37°C for three days. *Lactobacillus salivarius* (WB1004) and *L. brevis* (WB1005) were provided by the Wakamoto Pharmaceutical Company, Tokyo, Japan. The number of CFU of lactobacilli was counted on BL agar (Nissui, Tokyo, Japan) and identified as *Lactobacillus* using the API 50 CHL Kit (Biomerieux). For inoculation into mice, lactobacilli were grown in MRS broth (Difco) in 10% H₂, 10% CO₂, and 85% N₂ for one day. *Enterococcus faecalis* (No 19433) and *Staphylococcus aureus* (No 25923) were obtained from ATCC and grown on a BHI agar (Difco) plate.

**Adherence Assay**

An adherence assay was carried out by the method of Dunn et al with some modification. Briefly, 1×10⁵ of Kato III, MKN45, or murine gastric epithelial cells and varying numbers of fluorescent (PKH26) labelled lactobacilli were suspended in Hank’s gelatin salt solution (HGSS) and incubated at 37°C for 30 minutes in a 1.5 ml tube with gentle shaking. Fluorescent (PKH2) labelled *H. pylori* suspended in 0.1 ml HGSS was added to the tube and was incubated at 37°C for one hour. The non-adherent bacteria were removed by centrifugation with the addition of 9 ml 15% sucrose solution at 1000 rpm for 15 minutes. The cells were washed once with HGSS and were then analysed by flow cytometry using FACS Vantage (Becton Dickinson, Mountain View, California, USA). The machine was gated to include single cells but to exclude cell debris, clumps of cells, and non-adherent bacteria as described elsewhere. The labelling of *H. pylori* and lactobacillus with fluorescent dyes PKH2 (Dainippon Pharmaceutical Company, Tokyo, Japan) and PKH26 (Dainippon), respectively, was performed according to the manufacturer’s instructions. The emission waves from PKH2 and PKH26 were 504 nm and 567 nm, respectively. Kato III (gastric adenocarcinoma) and MKN45 (gastric carcinoma) cells were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). These cells were grown at 37°C in RPMI 1640 medium containing 10% FCS in 5% CO₂. Gastric epithelial cells were prepared from fresh stomachs of BALB/c germ free (GF) mice according to the method described by Kobayashi et al.

**Assay of IL-8 Produced in Cell Culture**

To measure the amount of IL-8 in the culture supernatant, 5×10⁵ MKN45 cells were suspended in 1-8 ml of RPMI 1640 medium containing 10% FCS and incubated at 37°C on a 24-well dish. One day after the start of incubation, varying numbers of lactobacilli (suspended in 0.1 ml of medium) were added to the dish, followed by 10⁸ *H. pylori* (suspended in 0.1 ml of medium) 30 min later. Six to 24 hours after incubation at 37°C, the supernatants were collected and IL-8 was measured by ELISA using the Quantikine Human IL-8 Immunoassay Kit (R&D Systems, Minneapolis, Minnesota, USA).

**Animals**

Animal treatment and care were carried out in accordance with the institutional guidelines of Tokai University. Male GF and specific pathogen-free (SPF) BALB/c mice were obtained from Nippon Clea Inc. (Tokyo, Japan). GF mice were maintained in Trexler type flexible film plastic isolators with sterile food and water as described previously. For infection with *H. pylori*, five-week-old mice were orally inoculated on three consecutive days with 1×10⁸ CFU of *H. pylori* that were freshly prepared and resuspended in 0.5 ml of phosphate buffered saline. To colonise mice by lactobacilli, 1×10⁸ CFU of lactobacilli suspended in 0.5 ml of phosphate buffered saline were orally inoculated once into four-week-old mice.

**Serum Antibody Titre**

Serum titre of IgG class antibody raised to *H. pylori* was measured by ELISA according to a method described previously. The antigen was a bacterial sonicate obtained by ultracentrifugation of *H. pylori* strain NCTC 11637. The absorbance reading was obtained from an appropriate dilution of serum whose titre was within the range in which a linear dose-absorbance relationship was available. A serum pool from GF mice at six weeks after infection with NCTC 11637 was regarded as the standard and was used to make the dose-absorbance plot.

**Gastric Pathology**

One half of each resected stomach along the greater curvature was fixed in 4% buffered formalin, and embedded in paraffin wax. Sections were stained with haematoxylin and eosin following standard procedures.
Results

INHIBITION OF ATTACHMENT OF *H pylori* TO GASTRIC EPITHELIAL CELLS BY LACTOBACILLI

To assess the effect of lactobacilli on the attachment of *H pylori* to gastric epithelial cells, *L salivarius*, one of the indigenous lactobacilli found in the human upper GI tract, was added to the culture for an adherence assay that consisted of fluorescent labelled *H pylori* and human gastric epithelial cell lines or murine gastric epithelial cells (fig 1). When the same number of *L salivarius* (1×10⁹) as that of *H pylori* No 130 was added to the assay culture, the number of *H pylori* adhering to both the Kato III and MKN45 cells decreased to less than one tenth the original number (fig 1A, B). Such a marked reduction in the attachment of *H pylori* to the cells by *L salivarius* was also found when murine gastric epithelial cells were used as indicator cells (fig 1C). A quantitative analysis of adherence inhibition using MKN45 cells demonstrated a close reverse correlation between the number of added *L salivarius* and that of *H pylori* attached to the cells (fig 2). Based on these plots, it was estimated that approximately 2×10⁵ *L salivarius* organisms were sufficient to reduce the number of adhering *H pylori* from 1×10⁹ to half that number. *L brevis* and *L acidophilus* also exhibited a significant but less marked inhibitory effect on the attachment of *H pylori* to the gastric epithelial cell lines (data not shown). In contrast to lactobacilli, neither *Enterococcus faecalis* nor *Staphylococcus aureus*, which are also found in the microflora of the GI tract, exerted any significant inhibitory effect on the adherence of *H pylori* to these cells (fig 1D).

SUPPRESSION OF *H pylori* MEDIATED RELEASE OF IL-8

To confirm the lactobacilli mediated inhibition of *H pylori* attachment, lactobacilli were added to the culture in which MKN45 cells were stimulated to secrete IL-8 by the attachment of...
H pylori (fig 3). Without the addition of lactobacilli, the amount of IL-8 accumulated in the culture supernatant increased progressively until 24 hours after the start of the culture (open circles). With addition of 10⁵ L salivarius, one tenth of the number of added H pylori significantly reduced the amount of IL-8 in the supernatant (fig 3A), while a ten times larger number was required to accomplish such a significant reduction by the addition of L brevis (fig 3B). The lactobacilli mediated suppression of IL-8 secretion was also observed when H pylori No 135 instead of No 130 was used as the stimulator (fig 3C). It was thus concluded that lactobacilli, especially L salivarius, efficiently inhibit the attachment of H pylori to gastric epithelial cells and the subsequent secretion of IL-8 by these cells. It was also interesting to note that the lactobacilli themselves hardly stimulated these human gastric epithelial cell lines to secrete IL-8 in this assay (open squares). In addition, no cytotoxic effect was found in the cells of this culture based on a microscopic analysis using trypan blue.

INOCULATION OF H PYLORI INTO GF AND SPF MICE
The gnotobiotic murine system was then used to determine whether or not colonisation of the stomach by H pylori can also be prevented by lactobacilli which can inhibit the attachment of H pylori to the cells in vitro. As shown in fig 1, we have confirmed that all of the H pylori strains including No 130, No 112 (data not shown), and NCTC 11637 (data not shown) have the ability to adhere to gastric epithelial cells in a primary culture obtained by the enzymatic digestion of the stomachs from GF BALB/c mice. First, susceptibility to colonisation by H pylori was compared between GF and SPF mice. Five-week-old mice were inoculated orally with H pylori No 112, No 130, or NCTC 11637, and the number of CFU of this bacterium colonising the stomach were counted (fig 4). In GF mice, all strains, including NCTC 11637, which has had no report of successful colonisation in the animal model so far, colonised the stomach in large numbers (around 10⁵ CFU per g tissue) one week after inoculation and still maintained such an overt infection nine weeks later (fig 4A). In SPF mice, however, no successful colonisation by any of these strains was found, while a transient colonisation by No 130 (open columns) was observed one week after inoculation (fig 4B). Examination of the specific IgG antibody titre to H pylori also substantiated the success and failure of the infection in GF and SPF mice, respectively, such that a significant elevation of the serum antibody titre was found three weeks after inoculation of any strain of H pylori in the GF mice while no such elevation was observed in the SPF mice (fig 5). Failure of the infection by H pylori in SPF mice thus raised the possibility that the microflora already colonising the stomach of these mice may inhibit colonisation by the H pylori inoculated later. Analysis of the composition of gastric bacterial flora in SPF mice revealed the predominant bacterial species to be lactobacilli, enterococci, and staphylococci in this order (table 1). Such findings strongly suggest that the inhibition of H pylori colonisation by lactobacilli actually occurs in the stomach of SPF mice.

INFECTION OF THE GNOTOBiotic MURINE SYSTEM BY H PYLORI
To confirm that L salivarius, which is a strain highly capable of inhibiting the attachment of H pylori to the cells in vitro, is also able to exert such an inhibitory effect on the colonisation and development of inflammatory lesions by H pylori in the stomach, GF mice were initially dosed with L salivarius by oral administration.
Prevention of Helicobacter pylori infection by lactobacilli

at four weeks and were then inoculated with *H. pylori* No 130 five weeks after birth (fig 6). The number of CFU of *L. salivarius* colonising the stomach was approximately 10^6 per g tissue when examined just before the inoculation of *H. pylori* (data not shown) and one, three, and six weeks after inoculation (fig 6B, shaded columns). As a control, five-week-old GF mice were prepared and inoculated orally with *H. pylori* No 130 only. While the stomachs of GF mice were colonised with a large number of *H. pylori* (fig 6A, open columns), the gnotobiotic mice, which had already been colonised by *L. salivarius*, had no detectable *H. pylori* after inoculation of this bacterium (fig 6B). The gnotobiotes associated with the lactobacilli of murine stomach origin, consisting of *L. acidophilus*, *L. delbrueckii*, and *L. fermentum*, were also completely protected from colonisation by *H. pylori* (fig 6C).

In contrast, neither the gnotobiotic mice infected with *E. faecalis* (fig 6D) nor the gnotobiotic mice infected with *S. aureus* (fig 6E) were able to inhibit colonisation by *H. pylori*, which was comparable to the results of the adherence assay in vitro in which both of these bacteria were unable to block the attachment of *H. pylori* to the cells (fig 1D). A significant elevation of the IgG antibody titre to *H. pylori* in GF, *E. faecalis* infected, and *S. aureus* infected mice together with the lack of any such rise in lactobacilli associated gnotobiotes, again confirmed the success and failure of infection by *H. pylori* in these two groups of mice, respectively (fig 6, open circles). A histological examination of the gastric mucosa nine weeks after inoculation of *H. pylori* No 130 demonstrated active gastritis in GF mice but no such lesions in *L. salivarius* infected gnotobiotic mice (fig 7). GF mice infected with No 112 did not develop any significant inflammatory lesions in the stomach (data not shown).

Finally, we investigated whether *L. salivarius* given after *H. pylori* colonisation can eliminate inhabiting *H. pylori*. GF mice infected with *H. pylori* at the age of five weeks were inoculated orally once a day for three consecutive days and thereafter once at 10, 11, and 12 weeks with 1 × 10^8 *L. salivarius*, and were sacrificed at 13 weeks of age for examination (fig 8). In the mice treated with *L. salivarius*, the number of *H. pylori* in the stomach decreased to less than one hundredth of that of *H. pylori* in the non-treated mice (open columns) and the antibody titre to *H. pylori* almost became undetectable (hatched columns), thus demonstrating the potential efficacy of *L. salivarius* as a probiotic against *H. pylori*.

**TABLE 1** Bacterial flora in the stomachs of mice

<table>
<thead>
<tr>
<th>Bacterial group</th>
<th>Bacterial number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactobacilli</td>
<td>8.5 (0.2)*</td>
</tr>
<tr>
<td><em>L. acidophilus</em></td>
<td>(~90%)</td>
</tr>
<tr>
<td><em>L. delbrueckii</em></td>
<td>(~10%)</td>
</tr>
<tr>
<td><em>L. fermentum</em></td>
<td>(~10%)</td>
</tr>
<tr>
<td>Enterococci</td>
<td>2.9 (0.5)</td>
</tr>
<tr>
<td>Staphylococci</td>
<td>2.9 (0.2)</td>
</tr>
<tr>
<td>Enterobacteria</td>
<td>2.9 (0.4)</td>
</tr>
<tr>
<td>Helicobacter</td>
<td>ND</td>
</tr>
</tbody>
</table>

Results expressed as log_{10} per g tissue (mean (SE)).

* n=3, ND, not detected.

---

**Figure 5:** Serum antibody titre to *H. pylori*. Serum from GF (A) and SPF (B) mice used in the experiment shown in fig 4 was assayed to examine its IgG class antibody titre to *H. pylori*. NT, not tested.

**Figure 6:** The number of *H. pylori* and antibody titre in gnotobiotic mice. GF (A), *L. salivarius* monoassociated gnotobiotic (B), murine stomach origin lactobacilli associated gnotobiotic (C), *E. faecalis* monoassociated gnotobiotic (D), and *S. aureus* monoassociated gnotobiotic (E) mice were inoculated with *H. pylori* No 130, and the number of CFU of *H. pylori* (open columns) and the other bacteria (shaded columns) colonizing their stomachs were counted one, three, and six weeks after inoculation. Serum IgG antibody titre to *H. pylori* were measured simultaneously (open circles). Bars represent the standard errors (n=5). ND, not detected.
Discussion

The adhesion of *H. pylori* to gastric epithelial cells is a primary event in the development of infection. A few putative cell receptors for *H. pylori* attachment have been identified including phosphatidyethanolamine,18 ganglioside GM3,19 and Lewis B antigens.20 Since most of these structures are also expressed on cells other than human, *H. pylori* can thus adhere to these non-human cells including those of murine origin as reported elsewhere.17 Nevertheless it was difficult to colonise experimental animals by *H. pylori*, except when these animals were maintained in GF and decontaminated conditions as in the cases of piglets21 and mice,11 respectively. In the present study, SPF mice were also unable to be colonised by *H. pylori* whereas GF mice were colonised easily by this bacterium. The difficulty in the colonisation by *H. pylori* in conventional mice may be explained by the large number of indigenous lactobacilli in their stomachs as shown in the present study. On the other hand, a very small number of lactobacilli inhabiting the stomachs of humans may permit *H. pylori* to colonise this organ easily.

Recently, Marchetti et al22 reported the successful colonisation by clinical isolates of *H. pylori* strains but not NCTC 11637, an established laboratory strain, in conventional and SPF mice. These findings may thus imply that such clinical isolates can adhere to the receptors on the cells so strongly as to overcome any competition with other indigenous bacteria such as lactobacilli, while NCTC 11637 is unable to attach itself so strongly. In contrast to their animal model, our GF murine system was able to be infected with any strain of *H. pylori* including NCTC 11637. Moreover in our animal model, active gastritis resembling human disease was observed in the infection with No 130, a vacuolating cytotoxin positive strain, but not with No 112, a vacuolating cytotoxin negative strain. This finding was consistent with the results shown by Marchetti et al23 and therefore demonstrated our system to be a reliable animal model of *H. pylori* infection.

Lactobacilli have been introduced into several fermented dairy products. There is a large body of evidence showing the positive role of exogenous lactobacilli in the prevention and treatment of GI disorders.24 Lactobacilli adhere to cells of the GI tract by secreting a proteaceous component, which serves as a bridge between the bacteria and eukaryotic cell receptors, although its precise nature still remains to be elucidated.25 This bacterium has been reported to inhibit the adhesion of many kinds of pathogenic enterobacteria to intestinal cells.26 While it is still unclear how lactobacilli inhibit the attachment of *H. pylori* to gastric epithelial cells in the present study, non-specific steric hindrance rather than a specific blockade of receptor sites is the most likely
Prevention of Helicobacter pylori infection by lactobacilli

mechanism, as lactobacilli can inhibit the adhesion of a large variety of bacteria, while each adheres to its particular receptor on the cells. Bharia et al. reported that *L. acidophilus* inhibits the growth of *H. pylori* in vitro, and thus concluded that this inhibitory effect is dependent on an extracellular secretory product, probably lactic acid. Such products secreted by lactobacilli may partially participate in the inhibition of colonisation by *H. pylori* in the stomachs of SPF and lactobacilli associated gnotobiotic mice.

Vaccination in addition to antimicrobial therapy will thus be needed in the campaign against *H. pylori*. However, a vaccine against *H. pylori* is still associated with some problems such as the unclarified effectiveness in prevention of infection and the resultant symptoms and potential noxious cross reaction with host tissue. The principle of probiotics, which involves feeding live bacteria to the host as a prophylactic or treatment for many intestinal diseases, has long been attempted. 26 If it is possible to establish a harmless organism in the gastric mucosa, colonisation by *H. pylori* can be prevented. The results of the present study suggest that lactobacillus is a good candidate for a probiotic against *H. pylori* as it can completely prevent the colonisation and subsequent gastric lesions caused by *H. pylori* in the stomach, possibly due to the inhibition of attachment. Furthermore, lactobacillus itself is considered to be a harmless organism in the gastric mucosa when it colonises the stomach, as this study showed that no pathological lesions developed in the stomach of gnotobiotic mice colonised by *L. salivarius*. Harmlessness of this bacterium in vitro was substantiated by the lack of significant production of IL-8 by the lactobacilli attached to the gastric epithelial cells in culture. Screening to find a more suitable strain of lactobacillus other than *L. salivarius* as a probiotic against *H. pylori* is underway.

Part of this study was financially assisted by the Sasagawa Fund for Medical Research, Tokyo, Japan.

Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model.

A M Kabir, Y Aiba, A Takagi, S Kamiya, T Miwa and Y Koga

Gut 1997 41: 49-55
doi: 10.1136/gut.41.1.49

Updated information and services can be found at:
http://gut.bmj.com/content/41/1/49

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Campylobacter, Salmonella, Shigella, Escherichia coli (242)
- Helicobacter pylori (218)
- Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/